With the European Medicines Agency (EMA) adopting a recommendation report to streamline the clinical procedures for ...
Real-world study shows plaque psoriasis stays controlled after 2 ustekinumab biosimilar switches, with stable labs and no ...
On March 30, 2026, the FDA approved Ponlimsi, a biosimilar to Prolia, and is reviewing a biosimilar candidate for Xolair.
Amgen Inc. (NASDAQ:AMGN) is one of the 10 best stocks to invest in during a recession. On February 27, 2026, Amgen Inc.
Week-18 ORR equivalence was achieved for HD204 vs reference bevacizumab (48.7% vs 46.5%), with both risk ratio and risk ...
The FDA approved Teva’s biosimilar for denosumab, and the FDA and EMA accepted its asthma biosimilar application for review.
U.S. regulators have proposed loosening some of the clinical trial requirements for companies to win approval for biosimilar versions of insulin products ...
Prestige Biopharma's Phase 3 SAMSON-II study reports successful results for HD204, a proposed biosimilar to Avastin, in ...
The European Medicines Agency has finalized its reflection paper on a tailored clinical approach to biosimilar development, ...
Israel-based Teva Pharmaceutical Industries today announced three milestones in its biosimilar portfolio, demonstrating ...
Fact: branded biologic drugs are consistently among the most expensive in our healthcare system. 1 Compounding this, chronic conditions – often treated with biologics – are becoming increasingly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results